Feline Diabetes Mellitus: Diagnosis and Management

At a Glance

Feline diabetes mellitus is a common endocrine disorder requiring systematic diagnosis and lifelong management. This article provides veterinary clinicians with a detailed clinical approach covering pathophysiology, diagnostic criteria, insulin therapy, dietary management, and monitoring protocols. The following table summarizes key diagnostic and management considerations.

Pathophysiology of Feline Diabetes Mellitus

Diabetes mellitus in cats results from impaired insulin secretion, insulin resistance, or both. The most common form resembles type 2 diabetes in humans, with pancreatic beta-cell dysfunction and peripheral insulin resistance. A distinct subset of diabetic cats have hypersomatotropism-induced diabetes secondary to acromegaly, which presents unique diagnostic and therapeutic challenges as described in the 2024 Journal of Feline Medicine and Surgery review of feline comorbidities (PubMed 38323402).

Obesity is a major risk factor for insulin resistance in cats. Adipose tissue releases pro-inflammatory cytokines and free fatty acids that impair insulin signaling at the cellular level. Chronic pancreatitis is another important contributor to diabetes development. The relationship between diabetes mellitus and pancreatitis is bidirectional, as reviewed in the Journal of Small Animal Practice (PubMed 25586806). Pancreatitis can destroy beta cells directly, while diabetic metabolic derangements may predispose to pancreatic inflammation.

Amyloid deposition within pancreatic islets is a common histopathologic finding in diabetic cats. Islet amyloid polypeptide accumulates and contributes to progressive beta-cell loss. This process may be irreversible in some cats, explaining why not all diabetic cats achieve remission even with optimal management.

The 2023 Veterinary Clinics of North America review of diabetes mellitus in cats and dogs provides comprehensive coverage of current understanding of disease mechanisms (PubMed 37028830). Understanding the underlying pathophysiology guides treatment decisions and prognostic discussions with owners.

Diagnostic Criteria and Workup

Persistent Hyperglycemia and Glucosuria

The diagnosis of feline diabetes mellitus requires documentation of persistent hyperglycemia with concurrent glucosuria. A single elevated blood glucose measurement is insufficient because stress hyperglycemia is common in cats during veterinary visits. Stress-induced hyperglycemia can reach 300-400 mg/dL in some cats, particularly those that are fractious or anxious.

To confirm persistent hyperglycemia, obtain a second blood glucose measurement after the cat has acclimated to the hospital environment or collect samples at home. Glucosuria should be present when blood glucose exceeds the renal threshold. Urine dipstick testing for glucose is a practical screening tool, but confirm with blood glucose measurement.

Fructosamine Measurement

Serum fructosamine concentration reflects average blood glucose over the preceding 2-3 weeks. This test is particularly useful for distinguishing stress hyperglycemia from true diabetes mellitus. A normal fructosamine value in a cat with elevated blood glucose suggests stress hyperglycemia instead of diabetes. Elevated fructosamine confirms sustained hyperglycemia consistent with diabetes.

Fructosamine is also valuable for monitoring treatment response. A decreasing trend indicates improving glycemic control, while persistently elevated values suggest inadequate insulin dosing or dietary noncompliance. Note that fructosamine can be falsely lowered in cats with hypoalbuminemia or hyperthyroidism.

Urinalysis

Complete urinalysis is essential in the diagnostic workup. Glucosuria confirms that hyperglycemia exceeds the renal threshold. Ketonuria indicates metabolic decompensation and risk for diabetic ketoacidosis. The presence of ketones warrants immediate intervention and hospitalization.

Urine culture is recommended because diabetic cats have increased risk for urinary tract infections. Bacteriuria may be present without pyuria in diabetic patients due to impaired leukocyte function. Asymptomatic bacteriuria can complicate glycemic control and should be treated based on culture and sensitivity results.

Additional Diagnostic Testing

Serum biochemistry profile and complete blood count are indicated to evaluate for concurrent diseases. Common comorbidities include chronic kidney disease, hyperthyroidism, pancreatitis, and hepatic lipidosis. Serum thyroxine measurement is recommended, particularly in older cats, because hyperthyroidism can cause insulin resistance.

Pancreatic lipase immunoreactivity testing may be helpful when pancreatitis is suspected. The relationship between diabetes and pancreatitis is well established, and concurrent pancreatitis complicates insulin therapy and dietary management (PubMed 25586806).

In cats with poorly regulated diabetes despite adequate insulin dosing, consider testing for hypersomatotropism. Acromegaly causes insulin resistance through growth hormone excess. Serum insulin-like growth factor-1 measurement is a screening test, with confirmatory testing including growth hormone suppression testing or pituitary imaging (PubMed 38323402).

The iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats provide updated recommendations for diagnostic workup (PubMed 41224734). These guidelines emphasize the importance of systematic evaluation for concurrent diseases that may affect treatment response.

Insulin Therapy

Insulin Types and Selection

Insulin therapy is the cornerstone of feline diabetes management. Several insulin formulations are available, with long-acting insulins generally preferred for initial therapy. The 2018 AAHA Diabetes Management Guidelines for Dogs and Cats provide recommendations for insulin selection and dosing (Elsevier 5326/JAAHA-MS-6822). More recent 2026 AAHA Diabetes Management Guidelines for Cats offer updated guidance specific to feline patients (Elsevier 5326/JAAHA-MS-7572).

Glargine insulin is a long-acting recombinant human insulin analog that provides relatively peakless activity over 12-24 hours in cats. It is often the first-choice insulin for newly diagnosed diabetic cats because of its consistent absorption and low risk of hypoglycemia. Detemir insulin is another long-acting option with similar pharmacokinetic properties.

Porcine lente insulin is an intermediate-acting insulin approved for use in cats in some countries. It has a peak effect at 4-8 hours and duration of 10-14 hours. Some cats require twice-daily dosing with lente insulin.

Neutral protamine Hagedorn insulin is an intermediate-acting insulin with a more pronounced peak and shorter duration than glargine or detemir. It is less commonly used in cats due to higher risk of hypoglycemia and need for twice-daily dosing.

The 1995 Veterinary Clinics of North America review of insulin therapy provides foundational principles that remain relevant for understanding insulin pharmacokinetics in small animals (Elsevier S0195-5616(95)50062-2). The 1999 Journal of the American Animal Hospital Association article on insulin therapy in cats offers additional historical context for insulin selection (Elsevier 15473317-35-4-269).

Dosing Protocols

Insulin therapy should be initiated at a conservative dose to minimize hypoglycemia risk. Starting doses are typically 0.25-0.5 U/kg body weight administered subcutaneously every 12 hours. For glargine and detemir, many clinicians start at 1-2 U per cat twice daily, regardless of body weight, and adjust based on response.

The iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats provide updated recommendations for insulin initiation and dose adjustment (PubMed 41224734). These guidelines emphasize individualization of therapy based on serial glucose monitoring.

Insulin should be administered subcutaneously in the scruff or lateral thorax. Rotate injection sites to prevent lipodystrophy. Use U-100 insulin syringes with half-unit markings for accurate dosing in cats. Insulin pens designed for human use can facilitate accurate dosing but require careful instruction for owners.

Dose Adjustment

Insulin dose adjustments should be based on serial blood glucose measurements. The goal is to maintain blood glucose between 100-250 mg/dL for most of the day while avoiding hypoglycemia. Adjust doses by 0.5-1 U increments, no more frequently than every 5-7 days, to allow the cat to reach steady state.

If blood glucose remains above 300 mg/dL throughout the day, increase the insulin dose. If nadir glucose falls below 100 mg/dL or clinical hypoglycemia occurs, decrease the dose. The nadir typically occurs 4-8 hours after insulin administration for intermediate-acting insulins and 6-10 hours for long-acting insulins.

SGLT2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors represent a novel therapeutic approach for feline diabetes. These oral medications block renal glucose reabsorption, promoting glucosuria and lowering blood glucose. A 2025 review in the Journal of Veterinary Pharmacology and Therapeutics discusses SGLT2 inhibitor use in feline diabetes management (PubMed 38954371).

SGLT2 inhibitors may be appropriate for cats with mild, uncomplicated diabetes and adequate renal function. They are not suitable for cats with diabetic ketoacidosis, significant renal impairment, or those requiring high insulin doses. Close monitoring for ketonuria is essential because SGLT2 inhibitors can precipitate euglycemic diabetic ketoacidosis.

Dietary Management

Nutritional Principles

Dietary modification is a critical component of feline diabetes management. The primary goal is to reduce postprandial glucose excursions and promote weight loss in overweight cats. Low-carbohydrate, high-protein diets are recommended because cats are obligate carnivores with limited ability to metabolize dietary carbohydrates.

Canned or wet foods are preferred over dry foods because they typically contain fewer carbohydrates and higher moisture content. The ideal diabetic diet contains less than 10-12% metabolizable energy from carbohydrates. Commercial prescription diets formulated for diabetic cats are available and meet these nutritional targets.

The 1995 Veterinary Clinics of North America review of nutritional therapy for diabetes mellitus established principles that remain relevant today (Elsevier S0195-5616(95)50055-5). These include consistent meal timing relative to insulin administration and avoidance of free-choice feeding.

Feeding Protocols

Feed diabetic cats twice daily, with meals timed to coincide with peak insulin activity. Administer insulin immediately after the cat has eaten to ensure adequate food intake. If the cat does not eat, reduce the insulin dose by 50% or withhold insulin until the next scheduled feeding.

For overweight cats, implement a gradual weight loss program targeting 1-2% body weight loss per week. Rapid weight loss can precipitate hepatic lipidosis. Calculate caloric intake based on ideal body weight and adjust as weight loss progresses.

Dietary Compliance

Owner compliance with dietary recommendations is a common challenge. Cats accustomed to dry food may refuse canned diets. Gradual transition over 7-10 days, mixing increasing proportions of the new food with the old, improves acceptance. Warming canned food to body temperature can enhance palatability.

Some cats require a combination of wet and dry food to maintain adequate caloric intake. In these cases, select a dry food with moderate carbohydrate content and limit portion size. Avoid treats high in carbohydrates or simple sugars.

Monitoring Glycemic Control

Blood Glucose Curves

Serial blood glucose measurement over 8-12 hours provides the most comprehensive assessment of glycemic control. A glucose curve involves measuring blood glucose every 2-4 hours after insulin administration to identify the nadir, peak effect, and duration of insulin action.

Glucose curves can be performed in the hospital or at home. Home monitoring reduces stress artifact and provides more representative data. Train owners to obtain blood samples from the ear margin or paw pad using a lancet device and portable glucometer validated for cats.

Interpret glucose curves in context of the cat's clinical signs. The goal is to maintain blood glucose between 100-250 mg/dL for most of the day. The nadir should not fall below 80-100 mg/dL. If the nadir is too low or too high, adjust insulin dose accordingly.

Continuous Glucose Monitoring

Continuous glucose monitoring systems provide real-time glucose readings every 5-15 minutes over 7-14 days. These devices consist of a subcutaneous sensor that measures interstitial glucose concentration. CGM is increasingly used in veterinary practice for detailed glycemic assessment.

CGM offers several advantages over traditional glucose curves. It captures glucose fluctuations that may be missed with intermittent sampling, detects nocturnal hypoglycemia, and reduces stress from repeated blood sampling. The 2026 AAHA Diabetes Management Guidelines for Cats discuss the role of CGM in feline diabetes management (Elsevier 5326/JAAHA-MS-7572).

Limitations of CGM include cost, sensor failure, and need for calibration with blood glucose measurements. Interstitial glucose lags behind blood glucose by 5-10 minutes, which is clinically insignificant for most monitoring purposes.

Fructosamine Monitoring

Serial fructosamine measurements every 4-8 weeks provide an objective assessment of glycemic control over the preceding 2-3 weeks. A decreasing trend indicates improving control, while stable or increasing values suggest inadequate therapy.

Fructosamine is particularly useful when glucose curves are difficult to obtain or when stress hyperglycemia confounds blood glucose interpretation. However, fructosamine does not detect hypoglycemic episodes and should be interpreted alongside clinical signs and blood glucose data.

Clinical Signs

Owner observation of clinical signs is an essential component of monitoring. Resolution of polydipsia, polyuria, and polyphagia indicates improving glycemic control. Weight stabilization or gain in underweight cats is a positive sign. Persistent clinical signs despite insulin therapy warrant reevaluation of the treatment plan.

Owners should maintain a daily log of insulin dose, appetite, water intake, urine output, and body weight. This log provides valuable information for dose adjustments and early detection of complications.

Diabetic Ketoacidosis

Pathophysiology and Risk Factors

Diabetic ketoacidosis is a life-threatening complication of diabetes mellitus characterized by hyperglycemia, ketonemia, and metabolic acidosis. DKA develops when insulin deficiency is severe enough to promote lipolysis and hepatic ketone production. Concurrent illness, such as pancreatitis, infection, or stress, often precipitates DKA.

The 2023 Veterinary Clinics of North America review of diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome in companion animals provides comprehensive guidance on diagnosis and management (PubMed 36898859). DKA requires emergency intervention and intensive care.

Clinical Presentation

Cats with DKA present with profound lethargy, anorexia, vomiting, and dehydration. Physical examination findings may include depression, hypothermia, and acetone odor on the breath. Kussmaul respirations indicate severe metabolic acidosis.

Diagnosis is confirmed by documenting hyperglycemia, ketonemia or ketonuria, and metabolic acidosis. Serum beta-hydroxybutyrate measurement is the most sensitive test for ketosis. Electrolyte abnormalities, particularly hypokalemia and hypophosphatemia, are common and require correction.

Emergency Management

Treatment of DKA requires intravenous fluid therapy, insulin administration, and correction of electrolyte abnormalities. Regular crystalline insulin is used for initial stabilization, administered as a constant rate infusion or intermittent intramuscular injections. Fluid therapy with isotonic crystalloids corrects dehydration and promotes renal glucose excretion.

Potassium supplementation is essential because insulin therapy drives potassium intracellularly, exacerbating hypokalemia. Monitor electrolytes every 4-6 hours during initial stabilization. Transition to subcutaneous long-acting insulin once the cat is eating and ketosis has resolved.

Prevention

Preventing DKA requires consistent insulin administration, monitoring for intercurrent illness, and early veterinary intervention when clinical signs worsen. Owners should be educated about signs of DKA and instructed to seek emergency care if the cat becomes anorexic, lethargic, or develops vomiting.

Cats with recurrent DKA or poor glycemic control should be evaluated for underlying causes such as insulin dosing errors, insulin resistance from concurrent disease, or owner noncompliance.

Comorbidities and Complications

Hypoglycemia

Hypoglycemia is the most serious complication of insulin therapy. Clinical signs include weakness, lethargy, ataxia, seizures, and coma. Severe hypoglycemia can be fatal if not treated promptly.

Risk factors for hypoglycemia include insulin overdose, missed meals, increased exercise, and concurrent illness that reduces food intake. Cats with diabetic remission may become hypoglycemic if insulin is continued at the same dose.

Treatment of hypoglycemia depends on severity. Conscious cats with mild signs can be fed a small amount of food or given oral glucose solution. Unconscious cats require intravenous dextrose administration. Owners should be instructed to keep glucose gel or syrup at home for emergency use.

Diabetic Remission

Diabetic remission, defined as normoglycemia without insulin therapy, occurs in 20-50% of cats with newly diagnosed diabetes. Remission is more likely in cats with good initial glycemic control, early diagnosis, and aggressive insulin therapy with long-acting insulins.

Factors associated with remission include use of glargine or detemir insulin, low-carbohydrate diet, and achievement of good glycemic control within the first 3-6 months of treatment. Cats that achieve remission may remain normoglycemic for months to years, but some eventually relapse.

Monitor cats in remission for recurrence of clinical signs. Periodic blood glucose or fructosamine measurements can detect early relapse. Owners should be advised to resume insulin therapy if clinical signs return.

Pancreatitis

Pancreatitis is a common comorbidity in diabetic cats. The relationship between diabetes and pancreatitis is complex, with each condition predisposing to the other (PubMed 25586806). Pancreatitis can cause insulin resistance and complicate glycemic control.

Clinical signs of pancreatitis include anorexia, vomiting, abdominal pain, and lethargy. Diagnosis is based on clinical signs, pancreatic lipase immunoreactivity testing, and abdominal ultrasound. Treatment includes supportive care, antiemetics, and pain management.

Hypersomatotropism

Hypersomatotropism is an important cause of insulin-resistant diabetes in cats. Growth hormone excess from a pituitary adenoma causes severe insulin resistance, requiring high insulin doses for glycemic control (PubMed 38323402).

Clinical features of acromegaly include large body size, broad facial features, prognathia inferior, and organomegaly. Diagnosis is confirmed by elevated IGF-1 concentration and pituitary imaging. Treatment options include radiation therapy, hypophysectomy, or medical management with somatostatin analogs.

Chronic Kidney Disease

Chronic kidney disease is common in older cats and may coexist with diabetes. CKD complicates diabetes management because it affects insulin clearance, appetite, and hydration status. Some cats with CKD develop insulin resistance, while others become more sensitive to insulin.

Monitor renal parameters regularly in diabetic cats. Adjust insulin doses based on appetite and clinical signs. Cats with advanced CKD may require reduced insulin doses due to decreased renal insulin clearance.

Practical Implementation Steps

Initial Stabilization

1. Confirm diagnosis with persistent hyperglycemia, glucosuria, and elevated fructosamine.
2. Evaluate for concurrent diseases with serum biochemistry, complete blood count, urinalysis, and urine culture.
3. Initiate insulin therapy with long-acting insulin at 1-2 U per cat twice daily.
4. Prescribe a low-carbohydrate, high-protein diet and instruct owner on feeding protocol.
5. Schedule recheck in 5-7 days for glucose curve and dose adjustment.

Owner Education

1. Demonstrate insulin administration technique and observe owner performing injection.
2. Instruct on proper insulin storage.
3. Teach blood glucose monitoring using ear margin or paw pad sampling.
4. Provide written instructions for hypoglycemia recognition and treatment.
5. Discuss signs of DKA and when to seek emergency care.

Ongoing Monitoring

1. Perform glucose curve or CGM every 2-4 weeks until stable glycemic control achieved.
2. Measure fructosamine every 4-8 weeks to assess long-term control.
3. Monitor body weight, appetite, water intake, and urine output weekly.
4. Adjust insulin dose by 0.5-1 U based on glucose curve results.
5. Recheck urine culture every 3-6 months or if clinical signs suggest infection.

Escalation Criteria

1. Persistent hyperglycemia despite insulin dose exceeding 1 U/kg per injection.
2. Clinical signs of hypoglycemia.
3. Development of ketonuria or clinical signs of DKA.
4. Unexplained weight loss or poor body condition.
5. Suspected insulin resistance from concurrent disease.

Records and Measurements

Daily Log

Owners should maintain a daily record including:

• Insulin dose and time of administration
• Appetite and amount of food consumed
• Water intake
• Urine output and frequency
• Body weight
• Any abnormal clinical signs

Glucose Curve Documentation

Record blood glucose values at each time point during glucose curve:

• Time 0 before insulin and feeding
• Time 2, 4, 6, 8, 10, and 12 hours after insulin
• Note nadir glucose and time of nadir
• Note any clinical signs during curve

Fructosamine Trends

Plot fructosamine values over time to assess response to therapy:

• Baseline at diagnosis
• Recheck at 4-8 weeks after insulin initiation
• Every 8-12 weeks once stable
• More frequent if dose adjustments or complications occur

Common Failure Patterns

Insulin Dosing Errors

Inaccurate insulin dosing is a common cause of poor glycemic control. Errors include using incorrect syringe type, failing to mix suspension insulins, injecting air instead of insulin, and administering inconsistent doses. Review owner technique at each recheck visit.

Dietary Noncompliance

Owners may continue feeding high-carbohydrate diets or treats despite recommendations. Some cats refuse dietary changes. Address dietary challenges proactively and offer alternatives that meet nutritional goals.

Somogyi Effect

The Somogyi effect occurs when insulin overdose causes hypoglycemia, triggering counter-regulatory hormone release that results in rebound hyperglycemia. This pattern is identified on glucose curve as hypoglycemia followed by hyperglycemia. Treatment involves reducing insulin dose.

Insulin Resistance

Insulin resistance is defined as persistent hyperglycemia despite insulin doses exceeding 1 U/kg per injection. Common causes include hypersomatotropism, pancreatitis, hyperthyroidism, infection, and obesity. Investigate underlying causes when insulin resistance is suspected.

Concurrent Disease

Intercurrent illness can destabilize glycemic control. Common concurrent diseases include urinary tract infection, pancreatitis, hyperthyroidism, chronic kidney disease, and dental disease. Screen for these conditions regularly and treat appropriately.

Welfare and Safety Context

Animal Welfare Considerations

Diabetes mellitus significantly impacts feline welfare if untreated. Polydipsia, polyuria, polyphagia, and weight loss cause discomfort and distress. Diabetic ketoacidosis is painful and life-threatening. Prompt diagnosis and effective management improve quality of life.

The World Organisation for Animal Health emphasizes the importance of animal health and welfare in veterinary practice (WOAH Animal Health and Welfare). Veterinarians have a responsibility to provide appropriate diabetes care and educate owners about treatment options.

Owner Commitment

Managing a diabetic cat requires significant owner commitment. Daily insulin injections, dietary management, and monitoring are time-consuming and costly. Discuss the long-term commitment with owners before initiating therapy. Some owners may elect euthanasia if they cannot provide adequate care.

Euthanasia Considerations

Euthanasia may be appropriate when diabetes cannot be adequately controlled despite optimal therapy, when owner resources are insufficient, or when concurrent diseases significantly impair quality of life. Discuss euthanasia options with owners who are struggling with diabetes management.

Practical Decision Framework for Insulin Dose Adjustment in Feline Diabetes

Systematic Approach to Dose Modification

Insulin dose adjustment in diabetic cats requires a structured decision framework that integrates glucose monitoring data, clinical signs, and recognition of confounding factors. Without a systematic approach, dose changes risk causing hypoglycemia or prolonging poor glycemic control. The 2026 AAHA Diabetes Management Guidelines for Cats emphasize individualization of therapy based on serial glucose monitoring (Elsevier 5326/JAAHA-MS-7572). The following framework provides a stepwise method for evaluating glucose curve data and making dose adjustments with defined escalation criteria.

Step 1: Evaluate Glucose Curve Quality and Validity

Before adjusting insulin dose, assess whether the glucose curve accurately represents the cat's typical glycemic response. A valid glucose curve requires the following conditions:

• The cat ate at least 75% of its meal before insulin administration
• Insulin was administered at the correct dose and via proper technique
• Blood glucose was measured at consistent intervals (every 2-4 hours for 12 hours)
• No intercurrent illness or stress event occurred during the curve period

If any of these conditions are not met, repeat the glucose curve before making dose adjustments. Stress hyperglycemia from hospitalization can invalidate in-hospital curves. The iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats recommend home glucose monitoring when possible to reduce stress artifact (PubMed 41224734).

Step 2: Identify the Nadir Glucose and Timing

The nadir is the lowest blood glucose value during the glucose curve. Record both the nadir glucose concentration and the time after insulin administration when it occurs. This information guides both dose adjustment and insulin type selection.

Interpret nadir values using the following thresholds:

• Nadir below 80 mg/dL: Hypoglycemia risk. Reduce insulin dose regardless of other curve values.
• Nadir 80-120 mg/dL: Good glycemic control. Maintain current dose if clinical signs are resolved.
• Nadir 121-200 mg/dL: Acceptable control. Consider small dose increase if clinical signs persist.
• Nadir above 200 mg/dL: Inadequate control. Increase insulin dose if no contraindications.

The timing of the nadir provides information about insulin pharmacokinetics. For long-acting insulins such as glargine or detemir, the nadir typically occurs 6-10 hours after administration. If the nadir occurs earlier than 4 hours, the insulin may have a shorter duration of action than expected. If the nadir occurs after 10 hours, the insulin may have prolonged activity that increases hypoglycemia risk during the next dosing interval.

Step 3: Assess Duration of Insulin Action

Duration of action is determined by the time interval during which blood glucose remains below 250 mg/dL after insulin administration. Adequate duration means blood glucose stays below 250 mg/dL for at least 8-10 hours of the 12-hour dosing interval.

If blood glucose rises above 250 mg/dL before 8 hours after insulin administration, the insulin duration is insufficient. Management options include:

• Increase insulin dose by 0.5-1 U to prolong duration
• Consider switching to a longer-acting insulin formulation
• Evaluate for insulin resistance from concurrent disease

If blood glucose remains below 100 mg/dL for more than 8 hours, the insulin duration may be excessive. Management options include:

• Decrease insulin dose by 0.5-1 U
• Consider switching to a shorter-acting insulin formulation
• Monitor for delayed hypoglycemia

Step 4: Evaluate for the Somogyi Effect

The Somogyi effect occurs when insulin overdose causes hypoglycemia, triggering counter-regulatory hormone release that produces rebound hyperglycemia. This pattern is identified on glucose curve as hypoglycemia (nadir below 80 mg/dL) followed by hyperglycemia (above 300 mg/dL) later in the curve.

Suspect Somogyi effect when:

• The glucose curve shows a biphasic pattern with low nadir followed by high values
• Clinical signs of hypoglycemia (lethargy, weakness, ataxia) are observed during the curve
• Fructosamine is paradoxically normal or low despite hyperglycemia at the end of the curve

Management of suspected Somogyi effect requires reducing the insulin dose by 0.5-1 U, not increasing it. Increasing the dose in response to post-hypoglycemic hyperglycemia worsens the cycle and increases hypoglycemia risk. Repeat the glucose curve 5-7 days after dose reduction to confirm resolution.

Step 5: Apply Dose Adjustment Rules

Use the following rules for dose adjustment based on glucose curve interpretation. Adjust doses by 0.5-1 U increments, no more frequently than every 5-7 days, to allow the cat to reach steady state.

Rule 1: Nadir below 80 mg/dL

• Action: Decrease insulin dose by 0.5-1 U
• Rationale: Hypoglycemia risk outweighs any benefit of current dose
• Monitoring: Repeat glucose curve in 5-7 days

Rule 2: Nadir 80-120 mg/dL with clinical signs resolved

• Action: Maintain current dose
• Rationale: Good glycemic control achieved
• Monitoring: Repeat glucose curve in 2-4 weeks

Rule 3: Nadir 80-120 mg/dL with persistent clinical signs

• Action: Increase insulin dose by 0.5 U
• Rationale: Clinical signs indicate inadequate control despite acceptable nadir
• Monitoring: Repeat glucose curve in 5-7 days

Rule 4: Nadir 121-200 mg/dL with duration less than 8 hours

• Action: Increase insulin dose by 0.5-1 U
• Rationale: Inadequate duration of action
• Monitoring: Repeat glucose curve in 5-7 days

Rule 5: Nadir 121-200 mg/dL with duration 8-12 hours

• Action: Maintain current dose if clinical signs resolved
• Rationale: Acceptable control
• Monitoring: Repeat glucose curve in 2-4 weeks

Rule 6: Nadir above 200 mg/dL

• Action: Increase insulin dose by 0.5-1 U
• Rationale: Inadequate glycemic control
• Monitoring: Repeat glucose curve in 5-7 days

Rule 7: Suspected Somogyi effect

• Action: Decrease insulin dose by 0.5-1 U
• Rationale: Hypoglycemia triggering rebound hyperglycemia
• Monitoring: Repeat glucose curve in 5-7 days

Step 6: Integrate Clinical Signs and Fructosamine

Glucose curve data must be interpreted alongside clinical signs and fructosamine measurements. A cat with excellent glucose curve values but persistent polydipsia and polyuria may have concurrent disease causing these signs. Conversely, a cat with mildly elevated glucose curve values but complete resolution of clinical signs may be adequately controlled.

Fructosamine provides a 2-3 week average of glycemic control. Use fructosamine trends to confirm that dose adjustments are producing sustained improvement:

• Decreasing fructosamine over 4-8 weeks indicates improving control
• Stable fructosamine with good glucose curves indicates adequate control
• Increasing fructosamine despite dose increases suggests insulin resistance

The 2018 AAHA Diabetes Management Guidelines for Dogs and Cats recommend using both glucose curves and fructosamine for comprehensive assessment (Elsevier 5326/JAAHA-MS-6822).

Step 7: Recognize When to Escalate

Escalation criteria indicate when standard dose adjustment is insufficient and further diagnostic investigation is needed. Escalate care when:

• Insulin dose exceeds 1 U/kg per injection without achieving glycemic targets
• Glucose curve shows persistent hyperglycemia above 300 mg/dL despite dose increases
• Recurrent hypoglycemia occurs at low insulin doses
• Clinical signs of DKA develop
• Unexplained weight loss or poor body condition persists

When escalation criteria are met, investigate for underlying causes of insulin resistance. Common causes include:

• Hypersomatotropism: Test serum IGF-1 concentration. The 2024 Journal of Feline Medicine and Surgery review of hypersomatotropism-induced diabetes provides guidance on diagnosis and management (PubMed 38323402).
• Pancreatitis: Measure pancreatic lipase immunoreactivity. The relationship between diabetes and pancreatitis is well established (PubMed 25586806).
• Hyperthyroidism: Measure serum thyroxine concentration.
• Chronic infection: Perform urine culture, dental examination, and imaging as indicated.
• Obesity: Assess body condition score and implement weight loss program.

Record System for Dose Adjustments

Maintain a structured record for each dose adjustment to track patterns and outcomes. The following template captures essential information:

Dose Adjustment Record

Include space for owner comments about appetite, water intake, and any abnormal observations. Review this record at each recheck visit to identify trends and avoid repeating ineffective adjustments.

Common Failure Patterns in Dose Adjustment

Pattern 1: Frequent Dose Increases Without Improvement

Some clinicians increase insulin dose repeatedly when glucose curves show persistent hyperglycemia. This pattern fails when the underlying problem is insulin resistance instead of insufficient dose. Suspect insulin resistance when doses exceed 1 U/kg per injection without achieving glycemic targets. Investigate for concurrent disease before further dose increases.

Pattern 2: Dose Reduction After Every Hypoglycemic Episode

While dose reduction is appropriate after hypoglycemia, some cats have intermittent hypoglycemia due to variable appetite or activity. In these cases, identify the pattern of hypoglycemia and adjust the dose based on the nadir from a glucose curve instead of a single low reading. Consider continuous glucose monitoring for cats with unpredictable glucose fluctuations.

Pattern 3: Ignoring the Somogyi Effect

The Somogyi effect is frequently missed because post-hypoglycemic hyperglycemia appears to indicate inadequate control. Always examine the full glucose curve for a biphasic pattern before increasing dose. If the nadir is below 80 mg/dL at any point, reduce the dose regardless of later hyperglycemia.

Pattern 4: Adjusting Dose Based on Single Blood Glucose Readings

Single blood glucose measurements do not provide sufficient information for dose adjustment. A single high reading may occur at the end of the dosing interval when insulin effect is waning, while a single low reading may occur at the nadir. Always use a full glucose curve or continuous glucose monitoring data for dose decisions.

Welfare and Safety Context for Dose Adjustment

The primary safety concern in insulin dose adjustment is hypoglycemia. Hypoglycemia causes clinical signs ranging from lethargy to seizures and can be fatal if untreated. The World Organisation for Animal Health emphasizes the importance of animal health and welfare in veterinary practice (WOAH Animal Health and Welfare). Veterinarians must prioritize hypoglycemia prevention over achieving perfect glycemic control.

Owner education about hypoglycemia recognition and treatment is essential. Provide written instructions for emergency management and ensure owners have glucose gel or syrup at home. Instruct owners to contact the clinic immediately if hypoglycemia occurs.

Diabetic ketoacidosis is another safety concern. The 2023 Veterinary Clinics of North America review of diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome provides guidance on prevention and management (PubMed 36898859). Educate owners about signs of DKA and when to seek emergency care.

Professional Escalation Criteria

Refer to a veterinary internal medicine specialist when:

• Insulin dose exceeds 1.5 U/kg per injection without glycemic control
• Continuous glucose monitoring shows unexplained glucose variability
• Suspected hypersomatotropism requires advanced diagnostic testing
• Diabetic ketoacidosis is recurrent or severe
• Concurrent diseases complicate management despite optimal therapy

The iCatCare 2025 consensus guidelines recommend specialist referral for cats with persistent insulin resistance or complicated diabetes (PubMed 41224734). Early specialist involvement improves outcomes and reduces owner frustration.

Frequently Asked Questions

What is the difference between stress hyperglycemia and diabetes mellitus in cats?

Stress hyperglycemia is a transient elevation in blood glucose caused by catecholamine release during veterinary visits or other stressful events. It resolves when the stressor is removed. Diabetes mellitus involves persistent hyperglycemia due to insulin deficiency or resistance. Fructosamine measurement helps distinguish between the two conditions because fructosamine remains normal in stress hyperglycemia but is elevated in diabetes.

How is feline diabetes diagnosed?

Diagnosis requires documentation of persistent hyperglycemia with concurrent glucosuria. A single elevated blood glucose measurement is insufficient because stress hyperglycemia is common. Confirm with a second blood glucose measurement, fructosamine testing, and urinalysis demonstrating glucosuria. Additional testing may include serum biochemistry, complete blood count, urine culture, and thyroid testing to evaluate for concurrent diseases.

What insulin is best for cats?

Long-acting insulins such as glargine and detemir are generally preferred for initial therapy in cats. These insulins provide consistent absorption and low risk of hypoglycemia. Porcine lente insulin is an alternative in some countries. The choice of insulin depends on availability, cost, and individual patient response. The iCatCare 2025 consensus guidelines and AAHA guidelines provide recommendations for insulin selection (PubMed 41224734, Elsevier 5326/JAAHA-MS-7572).

How often should I monitor my diabetic cat?

Monitor blood glucose with glucose curves or continuous glucose monitoring every 2-4 weeks until stable glycemic control is achieved. Once stable, monitor every 2-4 months. Measure fructosamine every 4-8 weeks. Owners should monitor clinical signs daily and maintain a log of insulin dose, appetite, water intake, and body weight.

What should I do if my cat develops hypoglycemia?

Hypoglycemia is a medical emergency. If the cat is conscious and able to swallow, offer a small amount of food or administer oral glucose solution on the gums. If the cat is unconscious or seizing, seek emergency veterinary care immediately for intravenous dextrose administration. Reduce the insulin dose after a hypoglycemic episode and monitor closely.

Can diabetic cats achieve remission?

Yes, diabetic remission occurs in 20-50% of cats with newly diagnosed diabetes. Remission is more likely with early diagnosis, aggressive insulin therapy using long-acting insulins, low-carbohydrate diet, and good initial glycemic control. Cats that achieve remission may remain normoglycemic without insulin for months to years, but some eventually relapse.

What is diabetic ketoacidosis and how is it treated?

Diabetic ketoacidosis is a life-threatening complication characterized by hyperglycemia, ketonemia, and metabolic acidosis. Clinical signs include lethargy, anorexia, vomiting, and dehydration. Treatment requires emergency hospitalization for intravenous fluid therapy, insulin administration, and electrolyte correction. Prevention involves consistent insulin therapy and early veterinary intervention when clinical signs worsen.

What concurrent diseases are common in diabetic cats?

Common concurrent diseases include pancreatitis, chronic kidney disease, hyperthyroidism, urinary tract infections, and hypersomatotropism. These conditions can complicate diabetes management and require specific treatment. Regular screening for concurrent diseases is recommended, particularly in cats with poor glycemic control despite adequate insulin dosing.

Related Veterinary Guides

• Cat
• Clinical Biochemistry Urinalysis
• Hypertrophic Cardiomyopathy In Cats
• Prescription Medicine For Cats
• Sneezing Cat Remedy

References and Further Reading

• www.merckvetmanual.com
• catvets.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.. Journal of feline medicine and surgery, 2025.
• SGLT2 inhibitor use in the management of feline diabetes mellitus.. Journal of veterinary pharmacology and therapeutics, 2025.
• Diabetes mellitus and pancreatitis--cause or effect?. The Journal of small animal practice, 2015.
• Diabetes Mellitus in Cats and Dogs.. The Veterinary clinics of North America. Small animal practice, 2023.
• Diabetes Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome in Companion Animals.. The Veterinary clinics of North America. Small animal practice, 2023.
• Feline Comorbidities: Hypersomatotropism-induced diabetes in cats.. Journal of feline medicine and surgery, 2024.
• Insulin therapy in cats. Journal of the American Animal Hospital Association, 1999.
• 2018 AAHA Diabetes Management Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association, 2018.
• Insulin therapy. Veterinary Clinics of North America Small Animal Practice, 1995.
• 2026 AAHA Diabetes Management Guidelines for Cats. Journal of the American Animal Hospital Association, 2026.
• Nutritional therapy for diabetes mellitus.. Veterinary Clinics of North America Small Animal Practice, 1995.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.